Advertisement

Mu Opioid Receptor Mediated Analgesia and Reward

  • Howard L. FieldsEmail author
Chapter
Part of the The Receptors book series (REC)

Abstract

Agonists acting at the mu-opioid receptor (MOP-R) have two important functions related to motivational systems: (i) to suppress pain and (ii) to promote reward seeking. Their most important clinical application is for pain relief. In fact, MOP-R agonists are the most powerful analgesic agents currently available. The unparalleled therapeutic efficacy of MOP-R agonists undoubtedly results from the fact that they have several pain-inhibitory actions. They directly inhibit pain transmitting neurons in the periphery and central nervous system. They also act on descending pain modulatory circuits that control spinal cord pain transmission. In addition, MOP-R agonists produce powerful positive motivational effects. These effects are mediated by a circuit that includes dopaminergic neurons in the midbrain ventral tegmental area and their connections to limbic forebrain regions including sub-cortical areas such as the nucleus accumbens and amygdala. Because MOP-R agonists produce robust positive reinforcement, their repeated use can lead to addiction, which limits their use as analgesics. In this chapter, I will outline the actions of MOP-R agonists on the neural systems that transmit and modulate pain and at the central nervous system sites that underlie analgesia and reward.

Keywords

Pain Addiction Reward Motivation Medulla Spinal cord Midbrain Synapse 

References

  1. 1.
    Bushnell MC, Apkarian AV (2006) Representation of pain in the brain. In: McMahon SB, Koltzenburg M (eds) Wall and Melzack’s textbook of pain, 5th edn. Elsevier Churchill Livingstone, Edinburgh, pp 107–24Google Scholar
  2. 2.
    Craig AD (2002) How do you feel? Interoception: the sense of the physiological condition of the body. Nat Rev Neurosci 3(8):655–666PubMedGoogle Scholar
  3. 3.
    Stein C, Schafer M, Machelska H (2003) Attacking pain at its source: new perspectives on opioids. Nat Med 9(8):1003–1008PubMedGoogle Scholar
  4. 4.
    Gold MS, Levine JD (1996) DAMGO inhibits prostaglandin E2-induced potentiation of a TTX-resistant Na+ current in rat sensory neurons in vitro. Neurosci Lett 212(2):83–86PubMedGoogle Scholar
  5. 5.
    Joris JL, Dubner R, Hargreaves KM (1987) Opioid analgesia at peripheral sites: a target for opioids released during stress and inflammation? Anesth Analg 66(12):1277–1281PubMedGoogle Scholar
  6. 6.
    Kolesnikov YA, Jain S, Wilson R, Pasternak GW (1996) Peripheral morphine analgesia: synergy with central sites and a target of morphine tolerance. J Pharmacol Exp Ther 279(2):502–506PubMedGoogle Scholar
  7. 7.
    Stein C, Millan MJ, Shippenberg TS, Herz A (1988) Peripheral effect of fentanyl upon nociception in inflamed tissue of the rat. Neurosci Lett 84(2):225–228PubMedGoogle Scholar
  8. 8.
    Zhou L, Zhang Q, Stein C, Schafer M (1998) Contribution of opioid receptors on primary afferent versus sympathetic neurons to peripheral opioid analgesia. J Pharmacol Exp Ther 286(2):1000–1006PubMedGoogle Scholar
  9. 9.
    Smith EM (2003) Opioid peptides in immune cells. Adv Exp Med Biol 521:51–68PubMedGoogle Scholar
  10. 10.
    Labuz D, Mousa SA, Schafer M, Stein C, Machelska H (2007) Relative contribution of peripheral versus central opioid receptors to antinociception. Brain Res 1160:30–38PubMedGoogle Scholar
  11. 11.
    King M, Su W, Chang A, Zuckerman A, Pasternak GW (2001) Transport of opioids from the brain to the periphery by P-glycoprotein: peripheral actions of central drugs. Nat Neurosci 4(3):268–274PubMedGoogle Scholar
  12. 12.
    Yaksh TL, Noueihed R (1985) The physiology and pharmacology of spinal opiates. Annu Rev Pharmacol Toxicol 25:433–462PubMedGoogle Scholar
  13. 13.
    Yaksh TL, Rudy TA (1976) Analgesia mediated by a direct spinal action of narcotics. Science 192(4246):1357–1358PubMedGoogle Scholar
  14. 14.
    Cousins M, Mather L (1984) Intrathecal and epidural administration of opioids. Anesthesiology 61:276–310PubMedGoogle Scholar
  15. 15.
    Giovannelli M, Bedforth N, Aitkenhead A (2007) Survey of intrathecal opioid usage in the UK. Eur J Anaesthesiol 1–5Google Scholar
  16. 16.
    Todd AJK, Koerber HR (2006) Neuroanatomical substrates of spinal nociception. In: McMahon SB, Koltzenburg M (eds) Wall and Melzack’s textbook of pain, 5th edn. Elsevier Churchill Livingstone, Edinburgh, pp 73–90Google Scholar
  17. 17.
    Duggan AW, Hall JG, Headley PM (1976) Morphine, enkephalin and the substantia gelatinosa. Nature 264(5585):456–458PubMedGoogle Scholar
  18. 18.
    Fields HL, Emson PC, Leigh BK, Gilbert RFT, Iverson LL (1980) Multiple opiate receptor sites on primary afferent fibres. Nature 284:351–353PubMedGoogle Scholar
  19. 19.
    Grudt TJ, Williams JT (1994) μ-Opioid agonists inhibit spinal trigeminal substantia gelatinosa neurons in guinea pig and rat. J Neurosci 14:1646–1654PubMedGoogle Scholar
  20. 20.
    Glaum SR, Miller RJ, Hammond DL (1994) Inhibitory actions of δ1 δ2, and μ-opioid receptor agonists on excitatory transmission in lamina II neurons of adult rat spinal cord. J Neurosci 14:4965–4971PubMedGoogle Scholar
  21. 21.
    Allen BJ, Rogers SD, Ghilardi JR et al (1997) Noxious cutaneous thermal stimuli induce a graded release of endogenous substance P in the spinal cord: imaging peptide action in vivo. J Neurosci 17(15):5921–5927PubMedGoogle Scholar
  22. 22.
    Fields HL, Heinricher MM, Mason P (1991) Neurotransmitters in nociceptive modulatory circuits. Annu Rev Neurosci 14:219–245PubMedGoogle Scholar
  23. 23.
    Nichols ML, Allen BJ, Rogers SD et al (1999) Transmission of chronic nociception by spinal neurons expressing the substance P receptor. Science 286(5444):1558–1561PubMedGoogle Scholar
  24. 24.
    Jessell TM, Iversen LL (1977) Opiate analgesics inhibit substance P release from rat trigeminal nucleus. Nature 268:549–551PubMedGoogle Scholar
  25. 25.
    Mudge AW, Leeman SE, Fischbach GD (1979) Enkephalin inhibits release of substrate P from sensory neurons in culture and decreases action potential duration. Proc Nat Acad Sci USA 76:526–530Google Scholar
  26. 26.
    Di Chiara G, North RA (1992) Neurobiology of opiate abuse. Trends Pharmacol Sci 13(5):185–193PubMedGoogle Scholar
  27. 27.
    Yoshimura M, North RA (1983) Sustantia gelantinosa neurones hyperpolarised in vitro by enkephalin. Nature 305:529–530PubMedGoogle Scholar
  28. 28.
    Eckert WA III, McNaughton KK, Light AR (2003) Morphology and axonal arborization of rat spinal inner lamina II neurons hyperpolarized by mu-opioid-selective agonists. J Comp Neurol 458(3):240–256PubMedGoogle Scholar
  29. 29.
    Bennett GJ, Hayashi H, Abdelmoumene M, Dubner R (1979) Physiological properties of stalked cells of the substantia gelatinosa intracellularly stained with horseradish peroxidase. Brain Res 164:285–289PubMedGoogle Scholar
  30. 30.
    Light AR, Kavookjian AM (1988) Morphology and ultrastructure of physiologically identified substantia gelatinosa (lamina II) neurons with axons that terminate in deeper dorsal horn laminae (III–V). J Comp Neurol 267:172–189PubMedGoogle Scholar
  31. 31.
    North RA, Williams JT, Surprenant A, Christie MJ (1987) Mu and delta receptors belong to a family of receptors that are coupled to potassium channels. Proc Nat Acad Sci USA 84(15):5487–5491Google Scholar
  32. 32.
    Mansour A, Fox CA, Thompson RC, Akil H, Watson SJ (1994) mu-Opioid receptor mRNA expression in the rat CNS: comparison to mu-receptor binding. Brain Res 643(1–2):245–265PubMedGoogle Scholar
  33. 33.
    Yaksh TL (2006) Central pharmacology of nociceptive transmission. In: McMahon SB, Koltzenburg M (eds) Melzack & Wall’s textbook of pain, 5th edn. Elsevier Churchill Livingstone, Edinburgh, pp 371–414Google Scholar
  34. 34.
    Burkey AR, Carstens E, Wenniger JJ, Tang J, Jasmin L (1996) An opioidergic cortical antinociception triggering site in the agranular insular cortex of the rat that contributes to morphine antinociception. J Neurosci 16:6612–6623PubMedGoogle Scholar
  35. 35.
    Fields H (2004) State-dependent opioid control of pain. Nat Rev Neurosci 5(7):565–575PubMedGoogle Scholar
  36. 36.
    Fields HL, Basbaum AI, Heinricher MM (2006) Central nervous system mechanisms of pain modulation. In: McMahon SB, Koltzenburg M (eds) Melzack & Wall’s textbook of pain, 5th edn. Edinburgh, Elsevier Churchill Livingstone, pp 125–42Google Scholar
  37. 37.
    Mansour A, Fox CA, Watson SJ (1995) Opioid-receptor mRNA expression tn the rat CNS: anatomical and functional implications. Trends Neurosci 18:22–29PubMedGoogle Scholar
  38. 38.
    Darland T, Heinricher MM, Grandy DK (1998) Orphanin FQ/nociceptin: a role in pain and analgesia, but so much more. Trends Neurosci 21(5):215–221PubMedGoogle Scholar
  39. 39.
    Yaksh TL, Rudy TA (1978) Narcotic analgetics: CNS sites and mechanisms of action as revealed by intracerebral injection techniques. Pain 4:299–359PubMedGoogle Scholar
  40. 40.
    Mayer DJ, Price DD (1976) Central nervous system mechanisms of analgesia. Pain 2:379–404PubMedGoogle Scholar
  41. 41.
    Zemlan FP, Behbehani MM (1988) Nucleus cuneiformis and pain modulation: anatomy and behavioral pharmacology. Brain Res 453:89–102PubMedGoogle Scholar
  42. 42.
    Akil H, Mayer DJ, Liebeskind JC (1976) Antagonism of stimulation-produced analgesia by naloxone, a narcotic antagonist. Science 191(4230):961–962PubMedGoogle Scholar
  43. 43.
    Boivie J, Meyerson BA (1982) A correlative anatomical and clinical study of pain suppression by deep brain stimulation. Pain 13:113–126PubMedGoogle Scholar
  44. 44.
    Baskin DS, Mehler WR, Hosobuchi Y, Richardson DE, Adams JE, Flitter MA (1986) Autopsy analysis of the safety, efficacy and cartography of electrical stimulation of the central gray in humans. Brain Res 371:231–236PubMedGoogle Scholar
  45. 45.
    Bandler R, Keay KA (1996) Columnar organization in the midbrain periaqueductal gray and the integration of emotional expression. Prog Brain Res 107:285–300PubMedGoogle Scholar
  46. 46.
    Wager TD, Rilling JK, Smith EE et al (2004) Placebo-induced changes in FMRI in the anticipation and experience of pain. Science 303(5661):1162–1167PubMedGoogle Scholar
  47. 47.
    Aggleton JP (ed) (1992) The Amygdala: neurobiological aspects of emotion, memory and mental dysfunction. Wiley-Liss, New YorkGoogle Scholar
  48. 48.
    Rizvi TA, Ennis M, Behbehani MM, Shipley MT (1991) Connections between the central nucleus of the amygdala and the midbrain periaqueductal gray: topography and reciprocity. J Comp Neurol 303:121–131PubMedGoogle Scholar
  49. 49.
    Mansour A, Khachaturian H, Lewis ME, Akil H, Watson SJ (1988) Anatomy of CNS opioid receptors. Trends Neurosci 11(7):308–314PubMedGoogle Scholar
  50. 50.
    Pavlovic Z, Cooper M, Bodnar R (1996) Opioid antagonists in the periaqueductal gray inhibit morphine and betendorphin analgesia elicited form the amygdala of rats. Brain Res 741(1–2):13–26PubMedGoogle Scholar
  51. 51.
    Helmstetter FJ, Tershner SA, Poore LH, Bellgowan PSF (1998) Antinociception following opioid stimulation of the basolateral amygdala is expressed through the periaquaductal gray and rostal ventromedial medulla. Brain Res 779:104–118PubMedGoogle Scholar
  52. 52.
    Burstein R, Potrebic S (1993) Retrograde labeling of neurons in the spinal cord that project directly to the amygdala or the orbital cortex in the rat. J Comp Neurol 335:469–485PubMedGoogle Scholar
  53. 53.
    Gauriau C, Bernard JF (2004) A comparative reappraisal of projections from the superficial laminae of the dorsal horn in the rat: the forebrain. J Comp Neurol 468:24–56PubMedGoogle Scholar
  54. 54.
    Gauriau C, Bernard JF (2002) Pain pathways and parabrachial circuits in the rat. Exp Physiol 87(2):251–258PubMedGoogle Scholar
  55. 55.
    Gear RW, Aley KO, Levine JD (1999) Pain-induced analgesia mediated by mesolimbic reward circuits. J Neurosci 19(16):7175–7181PubMedGoogle Scholar
  56. 56.
    Zahm DS, Jensen SL, Williams ES, Martin JR III (1999) Direct comparison of projections from the central amygdaloid region and nucleus accumbens shell. Eur J Neurosci 11(4):1119–1126PubMedGoogle Scholar
  57. 57.
    Rhodes DL, Liebeskind JC (1978) Analgesia from rostral brain stem stimulation in the rat. Brain Res 143:521–532PubMedGoogle Scholar
  58. 58.
    Manning BH, Morgan MJ, Franklin KBJ (1994) Morphine analgesia in the formalin test: evidence for forebrain and midbrain sites of action. Neuroscience 63:289–294PubMedGoogle Scholar
  59. 59.
    Holden JE, Van Poppel AY, Thomas S (2002) Antinociception from lateral hypothalamic stimulation may be mediated by NK1 receptors in the A7 catecholamine cell group in rat. Brain Res 953(1–2):195–204PubMedGoogle Scholar
  60. 60.
    Beitz AJ (1982) The organisation of afferent projections to the midbrain periaqueductal grey of the rat. Neuroscience 7:133–159PubMedGoogle Scholar
  61. 61.
    Herbert H, Saper CB (1992) Organization of medullary adrenergic and noradrenergic projections to the periaqueductal gray matter in the rat. J Comp Neurol 315:34–52PubMedGoogle Scholar
  62. 62.
    Menetrey DA, Chaouch A, Binder D, Besson JM (1982) The origin of the spinomesencephalic tract in the rat: an anatomical study using the retrograde transport of horseradish peroxidase. J Comp Neurol 206:193–207PubMedGoogle Scholar
  63. 63.
    Keay KA, Feil K, Gordon BD, Herbert H, Bandler R (1997) Spinal afferents to functionally distinct periaqueductal gray columns in the rat: an anterograde and retrograde tracing study. J Comp Neurol 385(2):207–229PubMedGoogle Scholar
  64. 64.
    Chieng B, Christie MJ (1994) Hyperpolarization by opioids acting on mu-receptors of a sub-population of rat periaqueductal gray neurones in vitro. Br J Pharmacol 113:121–128PubMedGoogle Scholar
  65. 65.
    Chieng B, Christie MJ (1994) Inhibition by opioids acting on mu-receptors of GABAergic and glutamatergic postsynaptic potentials in single rat periaqueductal gray neurones in vitro. Br J Pharmacol 113(1):303–309PubMedGoogle Scholar
  66. 66.
    Williams JT, Christie MJ, Manzoni O (2001) Cellular and synaptic adaptations mediating opioid dependence. Phys Rev 81(1):299–343Google Scholar
  67. 67.
    Christie MJ, Vaughan CW, Ingram SL (1999) Opioids, NSAIDs and 5-lipoxygenase inhibitors act synergistically in brain via arachidonic acid metabolism. Inflamm Res 48(1):1–4PubMedGoogle Scholar
  68. 68.
    Moreau J-L, Fields HL (1986) Evidence for GABA involvement in midbrain control of medullary neurons that modulate nociceptive transmission. Brain Res 397:37–46PubMedGoogle Scholar
  69. 69.
    Beitz AJ (1982) The sites of origin of brainstem neurotensin and serotonin projections to the rodent nucleus raphe magnus. J Neurosci 2(7):829–842PubMedGoogle Scholar
  70. 70.
    Sagen J, Proudfit HK (1981) Hypoalgesia induced by blockade of noradrenergic projections to the raphe magnus: reversal by blockade of noradrenergic projections to the spinal cord. Brain Res 223:391–396PubMedGoogle Scholar
  71. 71.
    Rizvi TA, Murphy AZ, Ennis M, Behbehani MM, Shipley MT (1996) Medial preoptic area afferents to periaqueductal gray medullo-output neurons: a combined Fos and tract tracing study. J Neurosci 16(1):333–344PubMedGoogle Scholar
  72. 72.
    Hermann DM, Luppi PH, Peyron C, Hinckel P, Jouvet M (1997) Afferent projections to the rat nuclei raphe magnus, raphe pallidus and reticularis gigantocellularis pars alpha demonstrated by iontophoretic application of choleratoxin (subunit b). J Chem Neuroanat 13(1):1–21PubMedGoogle Scholar
  73. 73.
    Rossi GC, Pasternak GW, Bodnar RJ (1994) Mu and delta opioid synergy between the periaqueductal gray and the rostro-ventral medulla. Brain Res 665:85–93PubMedGoogle Scholar
  74. 74.
    Gebhart GF (1992) Can endogeneous systems produce pain? APS J 1:79–81Google Scholar
  75. 75.
    Fields HL, Heinricher MM (1985) Anatomy and physiology of a nociceptive modulatory system. Philos Trans R Soc Lond B 308:361–374Google Scholar
  76. 76.
    Fields HL, Malick A, Burstein R (1995) Dorsal horn projection targets of on and off cells in the rostral ventromedial medulla. J Neurophysiol 74:1742–1759PubMedGoogle Scholar
  77. 77.
    Heinricher MM, Morgan MM, Tortorici V, Fields HL (1994) Disinhibition of off-cells and antinociception produced by an opioid action within the rostral ventromedial medulla. Neuroscience 63:279–288PubMedGoogle Scholar
  78. 78.
    Bederson JB, Fields HL, Barbaro NM (1990) Hyperalgesia during naloxone-precipitated withdrawal from morphine is associated with increased on-cell activity in the rostral ventromedial medulla. Somatosens Motor Res 7:185–203Google Scholar
  79. 79.
    Heinricher MM, Barbaro NM, Fields HL (1989) Putative nociceptive modulating neurons in the rostral ventromedial medulla of the rat: firing of on- and off-cells is related to nociceptive responsiveness. Somatosens Motor Res 6(4):427–439Google Scholar
  80. 80.
    Ramirez F, Vanegas H (1989) Tooth pulp stimulation advances both medullary off–cell pause and tail flick. Neurosci Lett 100:153–156PubMedGoogle Scholar
  81. 81.
    Foo H, Mason P (2003) Discharge of raphe magnus on and off cells is predictive of the motor facilitation evoked by repeated laser stimulation. J Neurosci 23(5):1933–1940PubMedGoogle Scholar
  82. 82.
    Neubert MJ, Kincaid W, Heinricher MM. (2004) Nociceptive facilitating neurons in the rostral ventromedial medulla. Pain 110:158–165Google Scholar
  83. 83.
    Haws CM, Williamson AM, Fields HL (1989) Putative nociceptive modulatory neurons in the dorsolateral pontomesencephalic reticular formation. Brain Res 483:272–282PubMedGoogle Scholar
  84. 84.
    Pan ZZ, Williams JT, Osborne PB (1990) Opioid actions on single nucleus raphe magnus neurons from rat and guinea-pig in vitro. J Physiol 427:519–532PubMedGoogle Scholar
  85. 85.
    Heinricher MM, Morgan MM, Fields HL (1992) Direct and indirect action of morphine on medullary neurons that modulate nociception. Neuroscience 48(3):533–543PubMedGoogle Scholar
  86. 86.
    Heinricher MM, McGaraughty S, Farr DA (1999) The role of excitatory amino acid transmission within the rostral ventromedial medulla in the antinociceptive actions of systemically administered morphine. Pain 81:57–65PubMedGoogle Scholar
  87. 87.
    Porreca F, Ossipov MH, Gebhart GF (2002) Chronic pain and medullary descending facilitation. Trends Neurosci 25(6):319–325PubMedGoogle Scholar
  88. 88.
    Heinricher MM, Pertovaara A, Ossipov MH (2003) Descending modulation after injury. In: Koltzenburg M (ed) Proceedings of the 10th World Congress on Pain, Progress in Pain Research and Management. IASP Press, Seattle, pp 251–260Google Scholar
  89. 89.
    Moore RY (1981) The anatomy of central serotonin neuron systems in the rat brain. In: Jacobs BL, Gelperin A (eds) Serotonin neurotransmission and behavior. MIT, Cambridge, pp 35–71Google Scholar
  90. 90.
    Potrebic SB, Fields HL, Mason P (1994) Serotonin immunoreactivity is contained in one physiological cell class in the rat rostral ventromedial medulla. J Neurosci 14:1655–1665PubMedGoogle Scholar
  91. 91.
    Gao K, Mason P (2000) Serotonergic raphe magnus cells that respond to noxious tail heat are not ON or OFF cells. J Neurophysiol 84(4):1719–1725PubMedGoogle Scholar
  92. 92.
    Gao K, Kim YH, Mason P (1997) Serotonergic pontomedullary neurons are not activated by antinociceptive stimulation in the periaqueductal gray. J Neurosci 17:3285–3292PubMedGoogle Scholar
  93. 93.
    Gao K, Chen DO, Genzen JR, Mason P (1998) Activation of serotonergic neurons in the raphe magnus is not necessary for morphine analgesia. J Neurosci 18(5):1860–1868PubMedGoogle Scholar
  94. 94.
    Le Bars D (1988) Neuronal serotonin. In: Osborne NM, Hamon M (eds) Serotonin and pain. Wiley, New York, pp 171–226Google Scholar
  95. 95.
    Headley PM, Duggan AW, Griersmith BT (1978) Selective reduction by noradrenaline and 5HT of nociceptive responses of cat dorsal horn neurons. Brain Res 145:185–189PubMedGoogle Scholar
  96. 96.
    Jordan LM, Kenshao DR, Martin RF, Haber LH, Willis WD (1978) Depression of primate spinothalamic tract neurons by iontophoretic application of 5-hydroxytryptamine. Pain 5:135–142PubMedGoogle Scholar
  97. 97.
    Hylden JLK, Wilcox GL (1983) Intrathecal serotonin in mice: analgesia and inhibition of a spinal action of substance P. Life Sci 33:789–795PubMedGoogle Scholar
  98. 98.
    Mason P, Gao K (1998) Raphe magnus serotonergic neurons tonically modulate nociceptive transmission. Pain Forum 7:143–150Google Scholar
  99. 99.
    Mason P (1997) Physiological identification of pontomedullary serotonergic neurons in the rat. J Neurophysiol 77:1087–1098PubMedGoogle Scholar
  100. 100.
    Mason P (2001) Contributions of the medullary raphe and ventromedial reticular region to pain modulation and other homeostatic functions. Annu Rev Neurosci 24:737–777PubMedGoogle Scholar
  101. 101.
    Proudfit HK (1992) The behavioural pharmacology of the noradrenergic system. In: Guilbaud G (ed) Towards the use of noradrenergic agonists for the treatment of pain. Elsevier, Amsterdam, pp 119–136Google Scholar
  102. 102.
    Budai D, Harasawa I, Fields HL (1998) Midbrain periaqueductal gray (PAG) inhibits nociceptive inputs to sacral dorsal horn nociceptive neurons through α2-adrenergic receptors. J Neurophysiol 80(5):2244–2254PubMedGoogle Scholar
  103. 103.
    Bajic D, Proudfit HK (1999) Projections of neurons in the periaqueductal gray to pontine and medullary catecholamine cell groups involved in the modulation of nociception. J Comp Neurol 405(3):359–379PubMedGoogle Scholar
  104. 104.
    Holden JE, Proudfit HK (1998) Enkephalin neurons that project to the A7 catecholamine cell group are located in nuclei that modulate nociception: ventromedial medulla. Neuroscience 83(3):929–947PubMedGoogle Scholar
  105. 105.
    Yeomans DC, Proudfit HK (1990) Projections of substance P–immunoreactive neurons located in the ventromedial medulla to the A7 noradrenergic nucleus of the rat demonstrated using retrograde tracing combined with immunocytochemistry. Brain Res 532(1–2):329–332PubMedGoogle Scholar
  106. 106.
    Hammond DL, Tyce GM, Yaksh TL (1985) Efflux of 5-hydroxytryptamine and noradrenaline into spinal cord superfusates during stimulation of the rat medulla. J Physiol 359:151–162PubMedGoogle Scholar
  107. 107.
    Yaksh TL (1979) Direct evidence that spinal serotonin and noradrenaline terminals mediate the spinal antinociceptive effects of morphine in the periaqueductal grey. Brain Res 160:180–185PubMedGoogle Scholar
  108. 108.
    Barbaro NM, Hammond DL, Fields HL (1985) Effects of intrathecally administered methysergide and yohimbine on microstimulation-produced antinociception in the rat. Brain Res 343:223–229PubMedGoogle Scholar
  109. 109.
    Yeomans DC, Proudfit HK (1992) Antinociception induced by microinjection of substance P into the A7 catecholamine cell group in the rat. Neuroscience 49:681–691PubMedGoogle Scholar
  110. 110.
    Fields HL, Levine JD (1984) Placebo analgesia: a role for endorphins? Trends in Neurosci 7:271–273Google Scholar
  111. 111.
    Akil H, Meng F, Devine DP, Watson SJ (1997) Molecular and neuroanatomical properties of the endogenous opioid system: implications for treatment of opiate addiction. Semin Neurosci 9:70–83Google Scholar
  112. 112.
    Millan MJ (2002) Descending control of pain. Prog Neurobiol 66(6):355–474PubMedGoogle Scholar
  113. 113.
    Zadina JE, Hackler L, Ge L, Kastin AJ (1997) A potent and selective endogenous agonist for the mu-opiate receptor. Nature 386:499–502PubMedGoogle Scholar
  114. 114.
    Chapman V, Diaz A, Dickenson AH (1997) Distinct inhibitory effects of spinal endomorphin-1 and endomorphin-2 on evoked dorsal horn neuronal responses in the rat. Br J Pharmacol 122(8):1537–1539PubMedGoogle Scholar
  115. 115.
    Stone LS, Fairbanks CA, Laughlin TM et al (1997) Spinal analgesic actions of the new endogenous opioid peptides endomorphin-1 and -2. Neuroreport 8:3131–3135PubMedGoogle Scholar
  116. 116.
    Goldberg IE, Rossi GC, Letchworth SR et al (1998) Pharmacological characterization of endomorphin-1 and endomorphin-2 in mouse brain. J Pharmacol Exp Ther 286:1007–1013PubMedGoogle Scholar
  117. 117.
    Schreff M, Schulz S, Wiborny D, Höllt V (1998) Immunofluorescent identification of endomorphin-2-containing nerve fibers and terminals in the rat brain and spinal cord. Neuroreport 9:1031–1034PubMedGoogle Scholar
  118. 118.
    Minami M, Maekawa K, Yabuuchi K, Satoh M (1995) Double in situ hybridization study on coexistence of m-, d- and k-opioid receptor mRNAs with preprotachykinin A mRNA in the rat dorsal root ganglia. Brain Res Mol Brain Res 30(2):203–210PubMedGoogle Scholar
  119. 119.
    Sanderson-Nydahl K, Skinner K, Julius D, Basbaum AI. (2004) Co-localization of endomorphin-2 and substance P in primary afferent nociceptors and effects of injury: a light and electron microscopic study in the rat. Eur J Neurosci 19:1789–1799Google Scholar
  120. 120.
    Tershner SA, Helmstetter FJ (2000) Antinociception produced by mu-opioid receptor activation in the amygdala is partly dependent on activation of mu-opioid and neurotensin receptors in the ventral periaqueductal gray. Brain Res 865(1):17–26PubMedGoogle Scholar
  121. 121.
    Kiefel JM, Rossi GC, Bodnar RJ (1993) Medullary μ and δ opioid receptors modulate mesencephalic morphine analgesia in rats. Brain Res 624:151–161PubMedGoogle Scholar
  122. 122.
    Roychowdhury SM, Fields HL (1996) Endogenous opioids acting at a medullary mu-opioid receptor contribute to the behavioral antinociception produced by GABA antagonism in the midbrain periaqueductal gray. Neuroscience 74:863–872PubMedGoogle Scholar
  123. 123.
    Al-Rodhan N, Chipkin R, Yaksh TL (1990) The antinociceptive effects of SCH-32615, a neutral endopeptidase (enkephalinase) inhibitor, microinjected into the periaqueductal, ventral medulla and amygdala. Brain Res 520:123–130PubMedGoogle Scholar
  124. 124.
    Gogas KR, Presley RW, Levine JD, Basbaum AI (1991) The antinociceptive action of supraspinal opioids results from an increase in descending inhibitory control: correlation of nociceptive behavior and c-fos expression. Neuroscience 42:617–628PubMedGoogle Scholar
  125. 125.
    Hammond DL, Presley R, Gogas KR, Basbaum AI (1992) Morphine or U-50, 488 suppresses Fos protein-like immunoreactivity in the spinal cord and nucleus tractus solitarii evoked by a noxious visceral stimulus in the rat. J Comp Neurol 315:244–253PubMedGoogle Scholar
  126. 126.
    Hôkfelt T, Terenius T, Kuypers HGJM, Dann O (1979) Evidence for enkephalin immunoreactive neurons in the medulla oblongata projecting to the spinal cord. Neurosci Lett 14:55–60PubMedGoogle Scholar
  127. 127.
    Fleetwood-Walker SM, Hope PJ, Mitchell R, El-Yassir N, Molony V (1988) The influence of opioid receptor subtypes on the processing of nociceptive inputs in the spinal dorsal horn of the cat. Brain Res 451:213–26PubMedGoogle Scholar
  128. 128.
    Zorman G, Belcher G, Adams JE, Fields HL (1982) Lumbar intrathecal naloxone blocks analgesia produced by microstimulation of the ventromedial medulla in the rat. Brain Res 236:77–84PubMedGoogle Scholar
  129. 129.
    Aimone LD, Jones SL, Gebhart GF (1987) Stimulation-produced descending inhibition from the periaqueductal gray and nucleus raphe magnus in the rat: mediation by spinal monoamines but not opioids. Pain 31:123–136PubMedGoogle Scholar
  130. 130.
    Levine JD, Lane SR, Gordon NC, Fields HL (1982) A spinal opioid synapse mediates the interaction of spinal and brain stem sites in morphine analgesia. Brain Res 236:85–91PubMedGoogle Scholar
  131. 131.
    Oshita S, Yaksh TL, Chipkin R (1990) The antinociceptive effects of intrathecally administered SCH32615, an enkephalinase inhibitor, in the rat. Brain Res 515:143–148PubMedGoogle Scholar
  132. 132.
    Dickenson AH, Sullivan AF, Fournie-Zaluski MC, Roques BP (1987) Prevention of degredation of endogenous enkephalins produces inhibition of nociceptive neurones in rat spinal cord. Brain Res 408:185–191PubMedGoogle Scholar
  133. 133.
    Budai D, Fields HL (1998) Endogenous opioid peptides acting at mu-opioid receptors in the dorsal horn contribute to midbrain modulation of spinal nociceptive neurons. J Neurosci 79:677–687Google Scholar
  134. 134.
    Watkins LR, Mayer DJ (1982) Organization of endogenous opiate and nonopiate pain control systems. Science 216:1185–1192PubMedGoogle Scholar
  135. 135.
    Watkins LR, Young EG, Kinscheck IB, Mayer JD (1983) The neural basis of footshock analgesia: the role of specific ventral medullary nuclei. Brain Res 276:305–315PubMedGoogle Scholar
  136. 136.
    Fanselow MS (1991) The midbrain periaqueductal gray as a coordinator of action in response to fear and anxiety. In: Depaulis A, Bandler R (eds) The midbrain periaqueductal gray matter. Plenum, New York, pp 151–173Google Scholar
  137. 137.
    Watkins LR, Cobelli DA, Mayer DJ (1982) Classical conditioning of front paw and hind paw footshock induced analgesia (FSIA): naloxone reversibility and descending pathways. Brain Res 243:119–132PubMedGoogle Scholar
  138. 138.
    Helmstetter FJ, Tershner SA (1994) Lesions of the periaqueductal gray and rostral ventromedial medulla disrupt antinociceptive but not cardiovascular aversive conditional responses. J Neurosci 14:7099–7108PubMedGoogle Scholar
  139. 139.
    Helmstetter FJ (1992) The amygdala is essential for the expression of conditioned hypoalgesia. Behav Neurosci 106:518–528PubMedGoogle Scholar
  140. 140.
    Helmstetter FJ, Landeira-Fernandez J (1990) Conditional hypoalgesia is attenuated by naltrexone applied to the periaqueductal gray. Brain Res 537:88–92PubMedGoogle Scholar
  141. 141.
    Foo H, Helmstetter FJ (1999) Hypoalgesia elicited by a conditioned stimulus is blocked by a μ, but not a δ or a k, opioid antagonist injected into the rostral ventromedial medulla. Pain 83(3):427–431PubMedGoogle Scholar
  142. 142.
    Emson PC, Corder R, Ratter SJ et al (1984) Regional distribution of pro-opiomelanocortin-derived peptides in the human brain. Neuroendocrinol 38:45–50Google Scholar
  143. 143.
    Pittius CW, Seizinger BR, Pasi A, Mehraein P, Herz A (1984) Distribution and characterization of opioid peptides derived from proenkephalin A in human and rat central nervous system. Brain Res 304:127–136PubMedGoogle Scholar
  144. 144.
    Levine JD, Gordon NC, Jones RT, Fields HL (1978) The narcotic antagonist naloxone enhances clinical pain. Nature 272:826–827PubMedGoogle Scholar
  145. 145.
    Gracely RH, Dubner R, Wolskee PJ, Deeter WR (1983) Placebo and naloxone can alter post-surgical pain by separate mechansims. Nature 306:264–265PubMedGoogle Scholar
  146. 146.
    Grevert P, Goldstein A (1985) Placebo analgesia, naloxone and the role of endogenous opioids. In: White L, Tursky B, Shwartz GE (eds) Placebo: theory, research and mechanisms. Guilford, New York, pp 332–350Google Scholar
  147. 147.
    Levine JD, Gordon NC, Fields HL (1978) The mechanism of placebo analgesia. Lancet 2:654–657PubMedGoogle Scholar
  148. 148.
    Benedetti F (1996) The opposite effects of the opiate antagonist naloxone and the cholecystokinin antagonist proglumide on placebo analgesia. Pain 64:535–543PubMedGoogle Scholar
  149. 149.
    Benedetti F, Mayberg HS, Wager TD, Stohler CS, Zubieta JK (2005) Neurobiological mechanisms of the placebo effect. J Neurosci 25(45):10390–10402PubMedGoogle Scholar
  150. 150.
    Petrovic P, Kalso E, Petersson KM, Ingvar M (2002) Placebo and opioid analgesia: imaging a shared neuronal network. Science 295(5560):1737–1740PubMedGoogle Scholar
  151. 151.
    Wager TD, Scott DJ, Zubieta JK (2007) Placebo effects on human mu-opioid activity during pain. Proc Natl Acad Sci USA 104(26):11056–11061PubMedGoogle Scholar
  152. 152.
    Fields HL (2007) Should we be reluctant to prescribe opioids for chronic non-malignant pain? Pain 129(3):233–234PubMedGoogle Scholar
  153. 153.
    Kieffer BL (1999) Opioids: first lessons from knockout mice. Trends Pharmacol Sci 20(1):19–26PubMedGoogle Scholar
  154. 154.
    Matthes HW, Maldonado R, Simonin F et al (1996) Loss of morphine-induced analgesia, reward effect and withdrawal symptoms in mice lacking the mu-opioid–receptor gene. Nature 383(6603):819–823PubMedGoogle Scholar
  155. 155.
    Tzschentke TM (1998) Measuring reward with the conditioned place preference paradigm: a comprehensive review of drug effects, recent progress and new issues. Prog Neurobiol 56(6):613–672PubMedGoogle Scholar
  156. 156.
    Tzschentke TM (2007) Measuring reward with the conditioned place preference (CPP) paradigm: update of the last decade. Addict Biol 12(3–4):227–462PubMedGoogle Scholar
  157. 157.
    Hall FS, Sora I, Uhl GR (2001) Ethanol consumption and reward are decreased in mu-opiate receptor knockout mice. Psychopharmacol (Berl) 154(1):43–49Google Scholar
  158. 158.
    Koob GF, Le Moal M (2006) Neurobiology of addiction. Elsevier, AmsterdamGoogle Scholar
  159. 159.
    Liebman JM, Cooper SJ (1989) The neuropharmacological basis of reward. Clarenden, OxfordGoogle Scholar
  160. 160.
    Fields HL, Hjelmstad GO, Margolis EB, Nicola SM (2007) Ventral tegmental area neurons in learned appetitive behavior and positive reinforcement. Annu Rev Neurosci 30:289–316PubMedGoogle Scholar
  161. 161.
    van der Kooy D, Mucha RF, O’Shaughnessy M, Bucenieks P (1982) Reinforcing effects of brain microinjections of morphine revealed by conditioned place preference. Brain Res 243(1):107–117PubMedGoogle Scholar
  162. 162.
    Bozarth MA, Wise RA (1984) Anatomically distinct opiate receptor fields mediate reward and physical dependence. Science 224(4648):516–517PubMedGoogle Scholar
  163. 163.
    Bozarth MA, Wise RA (1981) Intracranial self-administration of morphine into the ventral tegmental area in rats. Life Sci 28(5):551–555PubMedGoogle Scholar
  164. 164.
    Zangen A, Ikemoto S, Zadina JE, Wise RA (2002) Rewarding and psychomotor stimulant effects of endomorphin-1: anteroposterior differences within the ventral tegmental area and lack of effect in nucleus accumbens. J Neurosci 22(16):7225–7233PubMedGoogle Scholar
  165. 165.
    Olmstead MC, Franklin KB (1997) The development of a conditioned place preference to morphine: effects of microinjections into various CNS sites. Behav Neurosci 111(6):1324–1334PubMedGoogle Scholar
  166. 166.
    Laviolette SR, Nader K, van der Kooy D (2002) Motivational state determines the functional role of the mesolimbic dopamine system in the mediation of opiate reward processes. Behav Brain Res 129(1–2):17–29PubMedGoogle Scholar
  167. 167.
    Latimer LG, Duffy P, Kalivas PW (1987) mu-opioid receptor involvement in enkephalin activation of dopamine neurons in the ventral tegmental area. J Pharmacol Exp Ther 241(1):328–337PubMedGoogle Scholar
  168. 168.
    David V, Durkin TP, Cazala P (2002) Differential effects of the dopamine D2/D3 receptor antagonist sulpiride on self-administration of morphine into the ventral tegmental area or the nucleus accumbens. Psychopharmacology 160(3):307–317PubMedGoogle Scholar
  169. 169.
    Fenu S, Spina L, Rivas E, Longoni R, Di Chiara G (2006) Morphine-conditioned single-trial place preference: role of nucleus accumbens shell dopamine receptors in acquisition, but not expression. Psychopharmacology (Berl) 187(2):143–153Google Scholar
  170. 170.
    Hyman SE, Malenka RC, Nestler EJ (2006) Neural mechanisms of addiction: the role of reward-related learning and memory. Annu Rev Neurosci 29:565–598PubMedGoogle Scholar
  171. 171.
    Johnson SW, North RA (1992) Two types of neurone in the rat ventral tegmental area and their synaptic inputs. J Physiol 450:455–468PubMedGoogle Scholar
  172. 172.
    Johnson SW, North RA (1992) Opioids excite dopamine neurons by hyperpolarization of local interneurons. J Neurosci 12(2):483–488PubMedGoogle Scholar
  173. 173.
    Shoji Y, Delfs J, Williams JT (1999) Presynaptic inhibition of GABA(B)-mediated synaptic potentials in the ventral tegmental area during morphine withdrawal. J Neurosci 19(6):2347–2355PubMedGoogle Scholar
  174. 174.
    Wise RA (1996) Neurobiology of addiction. Curr Opin Neurobiol 6(2):243–251PubMedGoogle Scholar
  175. 175.
    Fantino M, Hosotte J, Apfelbaum M (1986) An opioid antagonist, naltrexone, reduces preference for sucrose in humans. Am J Physiol 251(1 pt 2):R91–R96PubMedGoogle Scholar
  176. 176.
    Yeomans MR, Gray RW (1997) Effects of naltrexone on food intake and changes in subjective appetite during eating: evidence for opioid involvement in the appetizer effect. Physiol Behav 62(1):15–21PubMedGoogle Scholar
  177. 177.
    Kelley AE, Baldo BA, Pratt WE, Will MJ (2005) Corticostriatal-hypothalamic circuitry and food motivation: integration of energy, action and reward. Physiol Behav 86(5):773–795PubMedGoogle Scholar
  178. 178.
    Zhang M, Kelley AE (2002) Intake of saccharin, salt, and ethanol solutions is increased by infusion of a mu-opioid agonist into the nucleus accumbens. Psychopharmacology (Berl) 159(4):415–423Google Scholar
  179. 179.
    Levine AS, Billington CJ (2004) Opioids as agents of reward-related feeding: a consideration of the evidence. Physiol Behav 82(1):57–61PubMedGoogle Scholar
  180. 180.
    Bodnar RJ, Lamonte N, Israel Y, Kandov Y, Ackerman TF, Khaimova E (2005) Reciprocal opioid-opioid interactions between the ventral tegmental area and nucleus accumbens regions in mediating mu agonist-induced feeding in rats. Peptides 26(4):621–629PubMedGoogle Scholar
  181. 181.
    Smith KS, Berridge KC (2007) Opioid limbic circuit for reward: interaction between hedonic hotspots of nucleus accumbens and ventral pallidum. J Neurosci 27(7):1594–1605PubMedGoogle Scholar
  182. 182.
    Tanda G, Di Chiara G (1998) A dopamine-mu1 opioid link in the rat ventral tegmentum shared by palatable food (Fonzies) and non-psychostimulant drugs of abuse. Eur J Neurosci 10(3):1179–1187PubMedGoogle Scholar
  183. 183.
    Yoshida M, Yokoo H, Mizoguchi K et al (1992) Eating and drinking cause increased dopamine release in the nucleus accumbens and ventral tegmental area in the rat: measurement by in vivo microdialysis. Neurosci Lett 139(1):73–76PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2011

Authors and Affiliations

  1. 1.Ernest Gallo Clinic & Research Center, Department of NeurologyUniversity of California San FranciscoEmeryvilleUSA

Personalised recommendations